[go: up one dir, main page]

WO2008084254A3 - Lignée cellulaire pour criblage de traitements de la maladie d'alzheimer - Google Patents

Lignée cellulaire pour criblage de traitements de la maladie d'alzheimer Download PDF

Info

Publication number
WO2008084254A3
WO2008084254A3 PCT/GB2008/000112 GB2008000112W WO2008084254A3 WO 2008084254 A3 WO2008084254 A3 WO 2008084254A3 GB 2008000112 W GB2008000112 W GB 2008000112W WO 2008084254 A3 WO2008084254 A3 WO 2008084254A3
Authority
WO
WIPO (PCT)
Prior art keywords
nucleic acid
alzheimer
cell line
protein
relates
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB2008/000112
Other languages
English (en)
Other versions
WO2008084254A2 (fr
Inventor
Joanne Taylor
Adam David Kline
Chantal Eveline Bazenet
Laura Jane Turner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eisai London Research Laboratories Ltd
Original Assignee
Eisai London Research Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai London Research Laboratories Ltd filed Critical Eisai London Research Laboratories Ltd
Publication of WO2008084254A2 publication Critical patent/WO2008084254A2/fr
Publication of WO2008084254A3 publication Critical patent/WO2008084254A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5058—Neurological cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/10—Applications; Uses in screening processes
    • C12N2320/12—Applications; Uses in screening processes in functional genomics, i.e. for the determination of gene function

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Pathology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention se rapporte à un procédé de criblage en vue de déterminer si une séquence d'acide nucléique candidate influence la production de protéine Aβ, ce procédé consistant à transfecter une cellule, dont un exemplaire a été déposé auprès de l'ECACC sous le numéro de dépôt 07010301, avec une séquence d'acide nucléique candidate, et à déterminer si le niveau de protéine Aβ est modifié. L'invention se rapporte également à des séquences d'acide nucléique identifiées par le procédé décrit, ainsi qu'aux utilisations de ces séquences d'acide nucléique pour la prévention de la maladie d'Alzheimer. L'invention se rapporte en outre à l'utilisation d'une cellule, dont un exemplaire a été déposé auprès de l'ECACC sous le numéro de dépôt 07010301, pour le criblage en vue de l'identification d'un agent candidat influençant la production de protéine Aβ par lesdites cellules.
PCT/GB2008/000112 2007-01-12 2008-01-14 Lignée cellulaire pour criblage de traitements de la maladie d'alzheimer Ceased WO2008084254A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0700645A GB0700645D0 (en) 2007-01-12 2007-01-12 Targets for disease therapy
GB0700645.5 2007-01-12

Publications (2)

Publication Number Publication Date
WO2008084254A2 WO2008084254A2 (fr) 2008-07-17
WO2008084254A3 true WO2008084254A3 (fr) 2008-10-02

Family

ID=37809892

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2008/000112 Ceased WO2008084254A2 (fr) 2007-01-12 2008-01-14 Lignée cellulaire pour criblage de traitements de la maladie d'alzheimer

Country Status (2)

Country Link
GB (1) GB0700645D0 (fr)
WO (1) WO2008084254A2 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0821624D0 (en) * 2008-11-26 2008-12-31 Eisai London Res Lab Ltd Assay
WO2010079340A2 (fr) 2009-01-08 2010-07-15 Eisai R & D Management Co., Ltd. Dosage
WO2011088059A1 (fr) * 2010-01-12 2011-07-21 Whitehead Institute For Biomedical Research Cellules de levure exprimant la bêta amyloïde et leurs utilisations
JP6655557B2 (ja) 2014-06-13 2020-02-26 ホワイトヘッド インスティテュート フォー バイオメディカル リサーチ アミロイドベータ発現構築物およびその使用
CN115177726B (zh) * 2021-04-01 2023-11-28 中国科学技术大学 Gpr34及其抑制剂在制备脱髓鞘相关疾病治疗药物中的用途

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040219610A1 (en) * 2003-03-14 2004-11-04 The General Hospital Corporation Methods and compositions for diagnosing, preventing, and treating Alzheimer's disease
WO2005092443A1 (fr) * 2004-03-26 2005-10-06 Cellzome Ag Traitement de maladies neurodegeneratives au moyen de la laptm4b
US20050266502A1 (en) * 2004-04-20 2005-12-01 Merchiers Pascal G Methods, compositions and compound assays for inhibiting amyloid-beta protein production
WO2006021810A1 (fr) * 2004-08-27 2006-03-02 Proteome Sciences Plc Méthodes et formulations en rapport avec la maladie d’alzheimer
WO2006096529A2 (fr) * 2005-03-07 2006-09-14 Novartis Ag Genes associes a des etats neurodegeneratifs
US20070280927A1 (en) * 2004-01-29 2007-12-06 Cellzome Ag Treatment Of Neurodegenerative Diseases By The Use Of Atp7a

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040219610A1 (en) * 2003-03-14 2004-11-04 The General Hospital Corporation Methods and compositions for diagnosing, preventing, and treating Alzheimer's disease
US20070280927A1 (en) * 2004-01-29 2007-12-06 Cellzome Ag Treatment Of Neurodegenerative Diseases By The Use Of Atp7a
WO2005092443A1 (fr) * 2004-03-26 2005-10-06 Cellzome Ag Traitement de maladies neurodegeneratives au moyen de la laptm4b
US20050266502A1 (en) * 2004-04-20 2005-12-01 Merchiers Pascal G Methods, compositions and compound assays for inhibiting amyloid-beta protein production
WO2006021810A1 (fr) * 2004-08-27 2006-03-02 Proteome Sciences Plc Méthodes et formulations en rapport avec la maladie d’alzheimer
WO2006096529A2 (fr) * 2005-03-07 2006-09-14 Novartis Ag Genes associes a des etats neurodegeneratifs

Also Published As

Publication number Publication date
GB0700645D0 (en) 2007-02-21
WO2008084254A2 (fr) 2008-07-17

Similar Documents

Publication Publication Date Title
FI4067496T3 (fi) ADAM6-hiiriä
NZ595305A (en) Methods and reagents for treatment and diagnosis of age-related macular degeneration
WO2013022953A3 (fr) Biomarqueur pour maladie d'alzheimer et/ou trouble léger cognitif, et son utilisation
WO2006020269A3 (fr) Biomarqueurs de maladie neurodegenerative
WO2011069992A3 (fr) Mutéines de la lipocaline 2 humaine (lcn2, hngal) ayant une affinité pour une cible donnée
WO2009085200A3 (fr) Anticorps anti-amyloïde et utilisations de ceux-ci
WO2009062051A3 (fr) Procédés et compositions pour thérapie par anticorps
WO2005072340A3 (fr) Nouveaux polynucleotides codant pour des polypeptides et leurs procedes d'utilisation
WO2008105797A3 (fr) Polynucléotides codant pour de nouveaux variants du pcsk9
WO2004066941A3 (fr) Profils d'expression destines au cancer du colon et procedes d'utilisation
WO2021087296A8 (fr) Compositions et méthodes de traitement de la surdité neurosensorielle à l'aide de systèmes à deux vecteurs pour l'otoferline
WO2012160563A3 (fr) Utilisation de la phosphorylation d'akt en tant que biomarqueur pour le pronostic et le traitement de maladies neurodégénératives
WO2007110623A3 (fr) Procédé de criblage
MX2012006512A (es) Metodos y reactivos para la deteccion mejorada de peptidos beta amiloides.
WO2008084254A3 (fr) Lignée cellulaire pour criblage de traitements de la maladie d'alzheimer
EP2374884A3 (fr) Molécules d'ARNmi isolées des cellules souches mésenchymateuses humaines
WO2008034016A3 (fr) Dosages pour détecter des protéines à l'état natif et identifier des composés qui modulent la stabilité desdites protéines
WO2008144761A3 (fr) Procédés et compositions pour l'identification et le traitement du lupus
WO2007093412A8 (fr) Periangioblastes du muscle squelettique et mesangioblastes du muscle cardiaque, procede d'isolation et leurs utilisations
WO2011012268A8 (fr) Utilisation d'une protéine mimecan pour évaluer une insuffisance cardiaque
BR112017020769A2 (pt) anticorpo ou fragmento de ligação, seq id no:3 ou seq id no:7, conjugado de anticorpo-fármaco (adc), composição farmacêutica, processo para produzir a composição farmacêutica, kit para diagnosticar um indivíduo que sofre de um distúrbio neurodegenerativo, método para diagnosticar um indivíduo que sofre de um distúrbio neurodegenerativo, uso do anticorpo ou fragmento de ligação, uso ex vivo de um peptídeo t14, método para identificar um agente candidato, ensaio para identificar um agente, método para identificar um agente que modula
WO2005112619A3 (fr) Nouvelles disruptions geniques, compositions et methodes associees
WO2006083797A3 (fr) Amelioration et protection en therapie cellulaire dans le cas de troubles neurologiques y compris la maladie de parkinson
Khelifa et al. PP1 phosphatase controls both daughter cell formation and amylopectin levels in Toxoplasma gondii
WO2007058968A3 (fr) Profils d’expression genique et procedes d’utilisation

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08701791

Country of ref document: EP

Kind code of ref document: A2